JP3660169B2 - Oral composition - Google Patents
Oral composition Download PDFInfo
- Publication number
- JP3660169B2 JP3660169B2 JP25167599A JP25167599A JP3660169B2 JP 3660169 B2 JP3660169 B2 JP 3660169B2 JP 25167599 A JP25167599 A JP 25167599A JP 25167599 A JP25167599 A JP 25167599A JP 3660169 B2 JP3660169 B2 JP 3660169B2
- Authority
- JP
- Japan
- Prior art keywords
- oral composition
- cationic
- vitamins
- weight
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims description 42
- 125000002091 cationic group Chemical group 0.000 claims description 22
- 239000003899 bactericide agent Substances 0.000 claims description 17
- 229940088594 vitamin Drugs 0.000 claims description 15
- 229930003231 vitamin Natural products 0.000 claims description 15
- 235000013343 vitamin Nutrition 0.000 claims description 15
- 239000011782 vitamin Substances 0.000 claims description 15
- 239000002736 nonionic surfactant Substances 0.000 claims description 14
- 230000000855 fungicidal effect Effects 0.000 claims description 9
- 239000000417 fungicide Substances 0.000 claims description 9
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 2
- 235000019156 vitamin B Nutrition 0.000 claims 1
- 239000011720 vitamin B Substances 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 description 18
- -1 luconium Chemical class 0.000 description 14
- 238000002156 mixing Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000000693 micelle Substances 0.000 description 8
- 230000010261 cell growth Effects 0.000 description 7
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 7
- 210000000214 mouth Anatomy 0.000 description 7
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 208000028169 periodontal disease Diseases 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 206010042674 Swelling Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 4
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229940042585 tocopherol acetate Drugs 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- SVIJYLPSHPPVQF-UHFFFAOYSA-N 2-[2,2-diaminoethyl(dodecyl)amino]acetic acid Chemical compound CCCCCCCCCCCCN(CC(N)N)CC(O)=O SVIJYLPSHPPVQF-UHFFFAOYSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 2
- ZYEMGPIYFIJGTP-UHFFFAOYSA-N O-methyleugenol Chemical compound COC1=CC=C(CC=C)C=C1OC ZYEMGPIYFIJGTP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000005844 Thymol Substances 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 239000002280 amphoteric surfactant Substances 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- XSIFPSYPOVKYCO-UHFFFAOYSA-N butyl benzoate Chemical compound CCCCOC(=O)C1=CC=CC=C1 XSIFPSYPOVKYCO-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 208000007565 gingivitis Diseases 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- 235000008160 pyridoxine Nutrition 0.000 description 2
- 239000011677 pyridoxine Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960000790 thymol Drugs 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- 239000006150 trypticase soy agar Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
- KRLBLPBPZSSIGH-CSKARUKUSA-N (6e)-3,7-dimethylnona-1,6-dien-3-ol Chemical compound CC\C(C)=C\CCC(C)(O)C=C KRLBLPBPZSSIGH-CSKARUKUSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- GKQHIYSTBXDYNQ-UHFFFAOYSA-M 1-dodecylpyridin-1-ium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+]1=CC=CC=C1 GKQHIYSTBXDYNQ-UHFFFAOYSA-M 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- HKKXJKUATKEWDT-UHFFFAOYSA-N 2-ethyl-2-(tetradecylamino)butanoic acid Chemical compound C(CCCCCCCCCCCCC)NC(C(=O)O)(CC)CC HKKXJKUATKEWDT-UHFFFAOYSA-N 0.000 description 1
- UCNXEGMKUYUZIW-UHFFFAOYSA-N 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol dodecanoic acid Chemical compound CC1=C(O)C(CO)=C(CO)C=N1.CCCCCCCCCCCC(O)=O UCNXEGMKUYUZIW-UHFFFAOYSA-N 0.000 description 1
- IMCSHHYECBJTOO-UHFFFAOYSA-N 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol;octanoic acid Chemical compound CCCCCCCC(O)=O.CCCCCCCC(O)=O.CC1=NC=C(CO)C(CO)=C1O IMCSHHYECBJTOO-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 108010001682 Dextranase Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- VJOAHSOOBLDGAW-UHFFFAOYSA-N N1=C(C)C(O)=C(CO)C(CO)=C1.C(C1=CC=CC=C1)(=O)O Chemical compound N1=C(C)C(O)=C(CO)C(CO)=C1.C(C1=CC=CC=C1)(=O)O VJOAHSOOBLDGAW-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241001149563 Streptococcus mutans ATCC 25175 Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- OVKDFILSBMEKLT-UHFFFAOYSA-N alpha-Terpineol Natural products CC(=C)C1(O)CCC(C)=CC1 OVKDFILSBMEKLT-UHFFFAOYSA-N 0.000 description 1
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940088601 alpha-terpineol Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- 229920006321 anionic cellulose Polymers 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 description 1
- QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical compound C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 description 1
- PXLWOFBAEVGBOA-UHFFFAOYSA-N dihydrochalcone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=CC(C(=O)CC(O)C=2C=CC(O)=CC=2)=C1O PXLWOFBAEVGBOA-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 108010000165 exo-1,3-alpha-glucanase Proteins 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229940094522 laponite Drugs 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229940116837 methyleugenol Drugs 0.000 description 1
- PRHTXAOWJQTLBO-UHFFFAOYSA-N methyleugenol Natural products COC1=CC=C(C(C)=C)C=C1OC PRHTXAOWJQTLBO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000007823 ocimene derivatives Chemical class 0.000 description 1
- 239000008041 oiling agent Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- FCHXJFJNDJXENQ-UHFFFAOYSA-N pyridoxal hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(C=O)=C1O FCHXJFJNDJXENQ-UHFFFAOYSA-N 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229940005657 pyrophosphoric acid Drugs 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 239000010668 rosemary oil Substances 0.000 description 1
- 229940058206 rosemary oil Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 239000010670 sage oil Substances 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- GQTHJBOWLPZUOI-FJXQXJEOSA-M sodium D-pantothenate Chemical compound [Na+].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GQTHJBOWLPZUOI-FJXQXJEOSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 229940068459 sodium pantothenate Drugs 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- XJPBRODHZKDRCB-UHFFFAOYSA-N trans-alpha-ocimene Natural products CC(=C)CCC=C(C)C=C XJPBRODHZKDRCB-UHFFFAOYSA-N 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 1
- 150000003698 vitamin B derivatives Chemical class 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Cosmetics (AREA)
Description
【0001】
【産業上の利用分野】
本発明は、口腔用組成物に関する。より詳細には、本発明は優れた殺菌効果を奏すると共に、炎症による腫脹、発赤、出血を緩和し得る口腔用組成物、特に歯周病の予防または治療に優れた口腔用組成物に関する。
【0002】
【従来の技術】
皮膚や口腔などのヒト身体部位には種々の微生物が存在し、種々の疾患を起こす原因因子となり得ることが知られている。従来、このような疾患を予防または治療することを目的として、種々のカチオン性殺菌剤を配合した化粧料が開発されている。
【0003】
一方、化粧料処方においては、一般的使用感向上のために添加した香料などの油成分を可溶化するために、可溶化剤を添加する必要がある。この可溶化剤としては通常界面活性剤が配合されているが、特に非イオン性界面活性剤である場合には一定濃度を超えるとその分子が水溶液中でミセルを形成する。しかしながら、このようにミセルが形成されると、カチオン性殺菌剤がその中に取り込まれる結果、自由な殺菌剤濃度が低下してその効果が充分発揮されず、配合する殺菌剤の濃度を上げる等の必要があり、安全性、経済性、殺菌効率の面から、必ずしも満足できるものばかりではなかった。
【0004】
このような界面活性剤ミセルヘの殺菌剤の取り込みの問題を解決する従来技術として、例えば特公平03−47245号公報には、カチオン性殺菌剤と非イオン性界面活性剤とを併用してなる口腔用組成物にチモールなどを配合することによって、殺菌剤の失活を効果的に防止できることが記載されている。また、特開平7−165546号公報には、非イオン性界面活性剤に特殊なカチオン性界面活性剤を配合し、表面をカチオン性に制御した混合ミセルを形成するため、静電気的な反発力により、塩化セチルピリジニウムのミセル中への侵入を防ぐことができると記載されている。さらに、特開平8−259428号公報には、シクロデキストリン類の配合によって、非イオン性界面活性剤によるカチオン性殺菌剤の殺菌効果の低下を抑制することができると記載されている。しかし、上記のいずれの場合にも、ビタミン類に関する検討はなされていない。
【0005】
【発明が解決しようとする課題】
本発明は、上述の問題を解消した、カチオン性殺菌剤の殺菌活性の低下を抑制するとともに細胞増殖促進作用を発揮し、種々の病原菌により発生する歯周疾患を緩和ないし予防または治療し得る口腔用組成物を提供することを目的とする。
【0006】
【課題を解決するための手段】
本発明者らはかかる事情に鑑み鋭意検討を重ねた結果、カチオン性殺菌剤と非イオン性界面活性剤との組み合わせに細胞増殖促進作用のあるビタミン類から選ばれた1種または2種以上を添加すると、殺菌剤の界面活性剤ミセルヘの取り込みが減少することによる殺菌効果の向上とビタミン類による細胞増殖促進作用との相乗効果によって優れた殺菌効果が奏されると共に、炎症による腫脹、発赤、出血を緩和ないし予防・治療し得ることを見出し、本発明を完成するに至った。
【0007】
すなわち、本発明は、カチオン性殺菌剤と非イオン性界面活性剤とビタミンB 5 、B 6 およびそれらの誘導体よりなる群から選択されるビタミン類とを配合し、カチオン性殺菌剤とビタミン類との配合比率が重量比で1:1〜1000:1であることを特徴とする可溶化系口腔用組成物(但し、フッ化物は配合しない)を提供するものである。
本発明によれば、効率的かつ優れた殺菌効果が示され、それとともに細胞増殖促進効果が示され、その結果、炎症による腫脹、発赤、出血、歯周炎、歯肉炎などの歯周疾患などを緩和ないし予防または治療し得る。
【0008】
【発明の実施の形態】
本発明の口腔用組成物で用いるカチオン性殺菌剤は、例えば、塩酸クロルヘキシジン、グルコン酸クロルヘキシジンなどのビスグアニド系、アルキルジメチルベンジルアンモニウム系などの第4級アンモニウム系などが挙げられるが、その中でも塩化ベンザルコニウム、塩化ベンゼトニウムおよび塩化アルキルトリメチルアンモニウムなどの水溶性の第4級アンモニウム系や、塩化ラウリルピリジニウムまたは塩化セチルピリジニウムなどのアルキルピリジニウム塩が好ましく、塩化セチルピリジニウムが最も好ましい。このカチオン性殺菌剤は単独または2種以上を組合せて配合することができ、単独または2種以上の合計量として、化粧用組成物全量に対して、0.001〜1.0重量%、好ましくは0.01〜0.1重量%配合することができる。カチオン性殺菌剤の配合量が0.001重量%より少ないと十分な殺菌効果が得られなくなる一方、1.0重量%より多いと製剤の安定性を損なうおそれがあるため好ましくない。
これらのカチオン性殺菌剤は、例えば、ムシ歯菌(Streptococcus mutans)、化膿菌(Staphylococcus aureus)に対して殺菌スペクトルを有し、これらの病原菌が原因菌となる、例えば歯周炎、歯肉炎などの歯周疾患に対して緩和効果ないし予防または治療効果を有する。
【0009】
つぎに、本発明の口腔用組成物で用いる非イオン性界面活性剤としては、ポリオキシエチレン硬化ヒマシ油、ポリオキシエチレンポリオキシプロピレンブロックコポリマー型、ショ糖脂肪酸エステル、ポリオキシエチレン脂肪酸エステル、ポリオキシエチレンソルビタン脂肪酸エステルなどの親水性非イオン性界面活性剤が挙げられる。特に、ポリオキシエチレン硬化ヒマシ油が好ましく、それらを単独または2種以上を組合せて配合することができる。この非イオン性界面活性剤の配合量は、単独または2種以上の合計量として、口腔用組成物全量に対して約0.01〜10重量%、好ましくは0.1〜5重量%の割合である。非イオン性界面活性剤の配合量が0.01重量%より少ないと香料などの油成分が十分に可溶化できず、一方10重量%より多いとカチオン性殺菌剤のミセル中への取り込みによる殺菌効果の低下が実用上問題となるので好ましくない。
【0010】
また、本発明の口腔用組成物で用いるビタミン類は、ジカプリル酸ピリドキシン、安息香酸ピリドキシン、ラウリン酸ピリドキシン、ジラウリル酸ピリドキシン、トリパルミチン酸ピリドキシン、リン酸ピリドキサール、塩酸ピリドキシン、塩酸ピリドキサール、塩酸ピリドキサミンなどのビタミンB6およびその誘導体、ならびにパントテン酸ナトリウムおよびパントテン酸カルシウムなどのビタミンB5およびその誘導体が好ましい。これらのビタミン類は単独または2種以上を組合せて配合することができる。
【0011】
また、これらのビタミン類は、単独または2種以上の合計量として、口腔用組成物全量に対して約0.001〜1.0重量%、好ましくは0.01〜0.1重量%の割合で配合することができる。ビタミン類の配合量が0.001重量%より少ないと十分な細胞増殖促進作用が発揮されず、一方1.0重量%より多いと製剤系における保存安定性が悪化するため好ましくない。
【0012】
本発明の口腔用組成物で用いるカチオン性殺菌剤と非イオン性界面活性剤との配合比率は重量比で1:1〜1:100、好ましくは1:4〜1:10である。また、本発明の口腔用組成物で用いるカチオン性殺菌剤とビタミン類との配合比率は重量比で1:1〜1000:1、好ましくは5:1〜500:1である。
【0013】
本発明の口腔用組成物は、好ましくは可溶化系などの非−乳化系の形態を有するものであり、より好ましくは透明ないし半透明の可溶化系である。
【0014】
本発明の組成物は、口腔用組成物とすることができる。詳細には、洗口剤、マウススプレー、デンタルリンス、局所塗布剤および他の外用手段とすることができる。
【0015】
また、本発明の口腔用組成物には前記の成分に加えて、種々の形態に応じて以下のような公知の口腔用組成物成分を本発明の効果を損なわない範囲でさらに配合することができる。
例えば、界面活性剤としては、例えばN−ラウリルジアミノエチルグリシン、N−ミリスチルジエチルグリシンなどのN−アルキルジアミノエチルグリシン、N−アルキル−N−カルボキシメチルアンモニウムベタイン、2−アルキル−1−ヒドロキシエチルイミダゾリンベタインナトリウムなどの両イオン性界面活性剤が挙げられる。これらの両イオン性界面活性剤は前記の非イオン性界面活性剤とは別に、単独または2種以上を組み合わせて配合することができ、その配合量は、通常、単独または2種以上の合計量として、口腔用組成物全量に対して0.01〜40重量%、好ましくは0.1〜30重量%である。
【0016】
また、湿潤剤または保湿剤としては、例えばソルビット、グリセリン、エチレングリコール、プロピレングリコール、1,3−ブチレングリコール、ポリエチレングリコール、ポリプロピレングリコール、キシリット、マルチット、ラクチットなどを単独または2種以上を組み合わせて配合することができる。配合量は、通常、単独または2種以上の合計量として、口腔用組成物全量に対して5〜70重量%である。
【0017】
また、増粘剤としては、カチオン性殺菌剤の性質を考える上に、カルボキシメチルセルロースナトリウムやカルボキシメチルヒドロキシエチルセルロースなどのアニオン性のセルロース誘導体は好ましくなく、例えばカチオン化ヒドロキシエチルセルロース、アルギン酸ナトリウムなどのアルカリ金属アルギネート、アルギン酸プロピレングリコールエステル、キサンタンガム、トラガントガム、カラヤガム、アラビヤガム、カラギーナンなどのガム類、ポリビニルアルコール、ポリアクリル酸ナトリウム、カルボキシビニルポリマー、ポリビニルピロリドンなどの有機増粘剤、シリカゲル、アルミニウムシリカゲル、ビーガム、ラポナイトなどの無機増粘剤などを単独または2種以上を組合せて配合することができる。この増粘剤の配合量は、単独または2種以上の合計量として、口腔用組成物全量に対して通常0.3〜5重量%である。
【0018】
また、本発明の口腔用組成物においては、例えばメントール、カルボン酸、アネトール、オイゲノール、サリチル酸メチル、リモネン、オシメン、n−デシルアルコール、シトロネール、α−テルピネオール、メチルアセタート、シトロネニルアセタート、メチルオイゲノール、シネオール、リナロール、エチルリナロール、チモール、スペアミント油、ペパーミント油、レモン油、オレンジ油、セージ油、ローズマリー油、珪皮油、シソ油、冬緑油、了子油、ユーカリ油、ピメント油などの香料もしくは香味料または清涼剤を単独または2種以上を組合せて配合することができる。これらの香料もしくは香味料または清涼剤の配合量は、単独または2種以上の合計量として、口腔用組成物全量に対して0.001〜3重量%、好ましくは0.001〜2重量%である。
【0019】
また、本発明の口腔用組成物には、甘味剤として、例えばサッカリンナトリウム、アセスルファームカリウム、ステビオサイド、ネオヘスペリジルジヒドロカルコン、グリチルリチン、ペリラルチン、タウマチン、アスパラチルフェニルアラニルメチルエステル、ρ−メトキシシンナミックアルデヒドなどを単独または2種以上を組合せて配合することができる。この甘味剤の配合量は、単独または2種以上の合計量として、口腔用組成物全量に対して0.01〜1重量%、好ましくは0.05〜0.5重量%である。
【0020】
また、本発明の口腔用組成物には、前記のカチオン性殺菌剤以外の薬効成分として、例えば酢酸dl−α−トコフェロール、コハク酸トコフェロール、またはニコチン酸トコフェロールなどのビタミンE類、ドデシルジアミノエチルグリシンなどの両イオン性殺菌剤、トリクロサン、イソプロピルメチルフェノールなどの非イオン性殺菌剤、デキストラナーゼ、アミラーゼ、プロテアーゼ、ムタナーゼ、リゾチーム、溶菌酵素(リテックエンザイム)などの酵素、トラネキサム酸やイプシロンアミノカプロン酸、アルミニウムクロルヒドロキシルアラントイン、ジヒドロコレステロール、グリチルリチン塩類、グリチルレチン酸、グリセロフォスフェート、クロロフィル、塩化ナトリウム、カロペプタイド、水溶性無機リン酸化合物などを、単独または2種以上を組み合わせて配合することができる。
【0021】
その他に、本発明の口腔用組成物には、その形態または用途に応じて、アルコールなどの溶剤;クエン酸、リン酸、リンゴ酸、ピロリン酸、乳酸、酒石酸、酢酸、硝酸、ケイ酸またはこれらの化学的に可能な塩や水酸化ナトリウムなどのpH調整剤;安息香酸ナトリウム、安息香酸エチル、安息香酸メチル、安息香酸ブチルなどの保存剤;酢酸トコフェロール(ビタミンE)、アスコルビン酸(ビタミンC)などの酸化防止剤などを適宜配合することができる。
【0022】
【実施例】
以下の実施例により本発明をさらに詳細するが、本発明はこれらの実施例に限定されるものではない。実施例中、%は特に断らない限り重量%である。
【0023】
実験例1.
殺菌力試験
ストレプトコッカス・ミュータンス(Streptococcus mutans)ATCC 25175号菌株をPBS液でOD560=0.3になるように調整し、下記の表1に示した組成物と30秒間反応させ、その0.1mlをポリオキシエチレンソルビタンモノオレエートを0.5%とレシチンを0.07%含む滅菌PBS水溶液10mlに移し、殺菌反応を停止させた。1分間攪拌した後、同じくポリオキシエチレンソルビタンモノオレエートとレシチンを含む9mlのPBS水溶液で段階希釈した。そして各希釈液を100μlずつ、ポリオキシエチレンソルビタンモノオレエートを0.5%とレシチンを0.07%含む不活化されたトリプチカーゼ・ソイ・アガー(TSA)培地に塗抹し、37℃、48時間培養した後、コロニーの数を計測し、下記評価基準に照らして殺菌効果を評価した。
【0024】
評価基準:
ネガティブコントロール(PBS水溶液)に比べて、生き残り菌数が下記の通りに表される。
〜 1/10 0
1/10 〜 1/102 +1
1/102 〜 1/103 +2
1/103 〜 1/104 +3
1/104 〜 +4
評価基準の数値が大きいほど殺菌効果が高いことを示す。
結果は第1表に示した。
【0025】
【表1】
【0026】
表1から明らかように、ビタミンB 5およびB6を配合した全ての実施例は、それらを無配合の塩化セチルピリジニウム(CPC)単独で構成した試験液の比較例1、2、3に比べて、殺菌効果が極めて優れていることが明らかである。また、比較例1と2および3から、界面活性剤ポリオキシエチレン硬化ヒマシ油またはポリオキシエチレンポリオキシプロピレングリコールによって、CPCの活性が低下し、殺菌効果が低下することが確認された。
また、ビタミン類は細胞増殖促進作用を示すので、添加によって、腫脹、発赤、出血といった歯周疾患症状の改善も期待できる。
【0027】
実施例5 マウススプレー
以下の処方により、常法に従い、マウススプレーを製造した。
成分名 配合量 ( % )
エタノール 10 . 0
グリセリン 20 . 0
ポリオキシエチレン硬化ヒマシ油(60E . O . ) 0 . 3
ビタミンB 6 0 . 01
香料 0 . 1
サッカリンナトリウム 0 . 1
塩化セチルピリジニウム 0 . 05
クエン酸ナトリウム 0 . 08
酢酸トコフェロール 0 . 02
精製水 残部
合 計 100 . 0
得られたマウススプレーについては、上記の殺菌力試験で評価した結果、殺菌効果の向上が認められた。
【0028】
【発明の効果】
本発明によれば、配合したビタミン類は非イオン性界面活性剤によるミセル中へのカチオン性殺菌剤の取り込みを阻止し、よって、優れた殺菌効果と細胞増殖促進作用を示す口腔用組成物が提供される。 [0001]
[Industrial applications]
The present invention relates to an oral composition. More particularly, the present invention exhibits an excellent fungicidal effect, swelling due to inflammation, redness, oral compositions can alleviate bleeding, to set Narubutsu especially for good oral cavity for preventing or treating periodontal disease.
[0002]
[Prior art]
It is known that various microorganisms exist in human body parts such as the skin and the oral cavity, and can be a causative factor causing various diseases. Conventionally, cosmetics containing various cationic fungicides have been developed for the purpose of preventing or treating such diseases.
[0003]
On the other hand, in a cosmetic formulation, it is necessary to add a solubilizer in order to solubilize oil components such as fragrances added to improve the general feeling of use. As this solubilizer, a surfactant is usually blended, but in the case of a nonionic surfactant, the molecule forms micelles in an aqueous solution when a certain concentration is exceeded. However, when micelles are formed in this way, as a result of the cationic bactericidal agent being incorporated therein, the free bactericidal agent concentration is lowered and the effect is not sufficiently exerted, and the concentration of the bactericide compounded is increased. In view of safety, economic efficiency, and sterilization efficiency, it was not always satisfactory.
[0004]
For example, Japanese Patent Publication No. 03-47245 discloses an oral cavity formed by using a combination of a cationic bactericidal agent and a nonionic surfactant as a conventional technique for solving such a problem of incorporating a bactericide into a surfactant micelle. Incorporation of thymol or the like into the composition for use can effectively prevent the inactivation of the bactericide. Further, in JP-A-7-165546, a special cationic surfactant is blended with a nonionic surfactant to form a mixed micelle whose surface is controlled to be cationic. It is described that cetylpyridinium chloride can be prevented from penetrating into micelles. Furthermore, Japanese Patent Application Laid-Open No. 8-259428 describes that the reduction of the bactericidal effect of the cationic bactericide due to the nonionic surfactant can be suppressed by blending cyclodextrins. However, in any of the above cases, no investigation has been made on vitamins.
[0005]
[Problems to be solved by the invention]
The present invention has solved the above problems, exhibit cell growth promoting action while suppressing a decrease in bactericidal activity of cationic bactericidal agents may be alleviated or preventing or treating periodontal disease that occur by various pathogens It aims at providing the composition for oral cavity .
[0006]
[Means for Solving the Problems]
As a result of intensive studies in view of such circumstances, the present inventors have obtained one or more selected from vitamins having a cell growth promoting action in a combination of a cationic bactericide and a nonionic surfactant. When added, an excellent bactericidal effect is achieved by an improvement in bactericidal effect due to a decrease in uptake of the fungicide into the surfactant micelle and a cell growth promoting action by vitamins, and swelling, redness due to inflammation, It has been found that bleeding can be alleviated, prevented or treated, and the present invention has been completed.
[0007]
That is, the present invention is formulated with a cationic bactericide and a non-ionic surfactant and vitamin B 5, B 6 and vitamins which are selected from the group consisting of their derivatives, and cationic bactericidal agent and vitamins The solubilized oral composition (however, fluoride is not blended) is characterized in that the blending ratio of is 1: 1 to 1000: 1 by weight .
According to the present invention, efficient and excellent sterilizing effect are shown with it is shown a cell growth promoting effect, so that the swelling due to inflammation, redness, bleeding, periodontal diseases such as periodontitis, gingivitis Do etc. may alleviate or prevent or treat.
[0008]
DETAILED DESCRIPTION OF THE INVENTION
Examples of the cationic fungicide used in the oral composition of the present invention include bisguanides such as chlorhexidine hydrochloride and chlorhexidine gluconate, and quaternary ammoniums such as alkyldimethylbenzylammonium. Water-soluble quaternary ammonium compounds such as luconium, benzethonium chloride and alkyltrimethylammonium chloride, and alkylpyridinium salts such as laurylpyridinium chloride or cetylpyridinium chloride are preferred, and cetylpyridinium chloride is most preferred. This cationic fungicide can be blended alone or in combination of two or more, and is 0.001 to 1.0% by weight, preferably based on the total amount of the cosmetic composition, alone or as a total of two or more. Can be blended in an amount of 0.01 to 0.1% by weight. If the amount of the cationic bactericidal agent is less than 0.001% by weight, a sufficient bactericidal effect cannot be obtained. On the other hand, if it exceeds 1.0% by weight, the stability of the preparation may be impaired.
These cationic biocides are, for example, insect Hakin (Streptococcus mutans), a bactericidal spectrum against the pyogenic bacteria (Staphylococcus aureus), these pathogens cause bacteria such periodontitis, it gingivitis having a relaxation effect to prophylactic or therapeutic effect on throat periodontal disease.
[0009]
Next, as the nonionic surfactant used in the oral composition of the present invention, polyoxyethylene hydrogenated castor oil, polyoxyethylene polyoxypropylene block copolymer type, sucrose fatty acid ester, polyoxyethylene fatty acid ester, poly Examples include hydrophilic nonionic surfactants such as oxyethylene sorbitan fatty acid esters. In particular, polyoxyethylene hydrogenated castor oil is preferable, and these can be blended alone or in combination of two or more. The amount of the nonionic surfactant is about 0.01 to 10% by weight, preferably 0.1 to 5% by weight, based on the total amount of the oral composition, alone or as a total of two or more. It is. If the blending amount of the nonionic surfactant is less than 0.01% by weight, oil components such as fragrances cannot be sufficiently solubilized. On the other hand, if the blending amount is more than 10% by weight, sterilization by incorporation of the cationic fungicide into the micelles. Since the reduction of the effect causes a practical problem, it is not preferable.
[0010]
Also, vitamins used in the oral compositions of the present invention, pyridoxine di caprylate, pyridoxine benzoic acid, lauric acid pyridoxine, dilauryl acid pyridoxine, tripalmitate pyridoxine, pyridoxal phosphate, pyridoxine hydrochloride, hydrochloric pyridoxal hydrochloride, etc. pyridoxamine vitamins of B 6 and derivatives thereof, and vitamin B 5 and derivatives thereof, such as sodium pantothenate and calcium pantothenate are preferred. These vitamins can be blended alone or in combination of two or more.
[0011]
These vitamins, as alone or two or more of the total amount, from about 0.001 to 1.0 wt% with respect to the oral composition the total amount, preferably 0.01 to 0.1 wt% It can mix | blend in a ratio . Not the amount of vitamin compound is exhibited sufficient cell growth promoting activity is less than 0.001 wt%, whereas undesirably storage stability is deteriorated in the formulation system is more than 1.0 wt%.
[0012]
The mixing ratio of the cationic bactericidal agent and the nonionic surfactant used in the oral composition of the present invention is 1: 1 to 1: 100, preferably 1: 4 to 1:10 by weight. Moreover, the compounding ratio of the cationic bactericidal agent and vitamins used in the composition for oral cavity of the present invention is 1: 1 to 1000: 1, preferably 5: 1 to 500: 1 by weight ratio.
[0013]
The oral composition of the present invention, good Mashiku non such solubilizing system - are those in the form of an emulsion system, more preferably a solubilization system of transparent or translucent.
[0014]
The compositions of the present invention can be a mouth luminal cavity composition. Specifically, it can be a mouthwash, a mouth spray, a dental rinse, a topical coating agent and other external means.
[0015]
Further, the oral composition of the present invention, in addition to the above components, can further be blended a known oral composition components such as the following in response to various forms within a range not to impair the effects of the present invention it can.
For example, as the surfactant, for example, N-alkyldiaminoethylglycine such as N-lauryldiaminoethylglycine, N-myristyldiethylglycine, N-alkyl-N-carboxymethylammonium betaine, 2-alkyl-1-hydroxyethylimidazoline Examples include amphoteric surfactants such as sodium betaine. These amphoteric surfactants can be blended alone or in combination of two or more, in addition to the nonionic surfactant, and the blending amount is usually a single or a total of two or more. As 0.01 to 40% by weight, preferably 0.1 to 30% by weight, based on the total amount of the oral composition.
[0016]
In addition, as the wetting agent or moisturizing agent, for example, sorbit, glycerin, ethylene glycol, propylene glycol, 1,3-butylene glycol, polyethylene glycol, polypropylene glycol, xylit, maltite, lactit, etc. are used alone or in combination of two or more. can do. The amount is usually 5 to 70% by weight based on the total amount of the oral composition, alone or as a total amount of two or more.
[0017]
In addition, as a thickener, anionic cellulose derivatives such as sodium carboxymethyl cellulose and carboxymethyl hydroxyethyl cellulose are not preferable in consideration of the properties of the cationic fungicide. For example, alkali metals such as cationized hydroxyethyl cellulose and sodium alginate are not preferable. Alginates, propylene glycol alginate, xanthan gum, tragacanth gum, karaya gum, arabic gum, carrageenan and other gums, polyvinyl alcohol, sodium polyacrylate, carboxyvinyl polymer, polyvinylpyrrolidone and other organic thickeners, silica gel, aluminum silica gel, vegam, laponite Inorganic thickeners such as these can be blended alone or in combination of two or more. The blending amount of this thickener is usually 0.3 to 5% by weight based on the total amount of the oral composition, either alone or as a total amount of two or more.
[0018]
Further, in the oral composition of the present invention, for example, menthol, carboxylic acid, anethole, eugenol, methyl salicylate, limonene, ocimene, n-decyl alcohol, citronell, α-terpineol, methyl acetate, citronenyl acetate, Methyl eugenol, cineole, linalool, ethyl linalool, thymol, spearmint oil, peppermint oil, lemon oil, orange oil, sage oil, rosemary oil, cinnamon oil, perilla oil, winter green oil, Ryoko oil, eucalyptus oil, pimento Perfumes such as oil or flavoring agents or refreshing agents can be used alone or in combination of two or more. The blending amount of these fragrances or flavoring agents or refreshing agents is 0.001 to 3% by weight, preferably 0.001 to 2% by weight, based on the total amount of the oral composition, alone or as a total of two or more. is there.
[0019]
In addition, the oral composition of the present invention includes, for example, saccharin sodium, acesulfame potassium, stevioside, neohesperidyl dihydrochalcone, glycyrrhizin, perilartin, thaumatin, asparatylphenylalanyl methyl ester, ρ-methoxycin as sweeteners. Namic aldehyde can be blended alone or in combination of two or more. The blending amount of the sweetener is 0.01 to 1% by weight, preferably 0.05 to 0.5% by weight, based on the total amount of the oral composition, alone or as a total of two or more kinds.
[0020]
The oral composition of the present invention contains, for example, vitamin E such as dl-α-tocopherol acetate, tocopherol succinate or tocopherol nicotinate, dodecyldiaminoethylglycine as a medicinal component other than the cationic fungicide. amphoteric disinfectant such as triclosan, a nonionic disinfectant such as isopropyl methyl phenol, dextranase, amylase, protease, mutanase, lysozyme, an enzyme such as lytic enzymes (Ritekku enzyme), preparative Ranekisamu acid or epsilon aminocaproic acid , Aluminum chlorohydroxyl allantoin, dihydrocholesterol, glycyrrhizin salts, glycyrrhetinic acid, glycerophosphate, chlorophyll, sodium chloride, caropeptide, water-soluble inorganic phosphate compounds, etc. Or it can mix | blend in combination of 2 or more types.
[0021]
In addition, the oral composition of the present invention includes a solvent such as alcohol; citric acid, phosphoric acid, malic acid, pyrophosphoric acid, lactic acid, tartaric acid, acetic acid, nitric acid, silicic acid, or these depending on the form or use. PH adjusters such as chemically possible salts of sodium and sodium hydroxide; preservatives such as sodium benzoate, ethyl benzoate, methyl benzoate, butyl benzoate; tocopherol acetate (vitamin E), ascorbic acid (vitamin C) Antioxidants such as can be appropriately blended.
[0022]
【Example】
The present invention will be described in more detail by the following examples, but the present invention is not limited to these examples. In Examples,% is% by weight unless otherwise specified.
[0023]
Experimental Example 1.
Bactericidal activity test Streptococcus mutans ATCC 25175 strain was adjusted to OD 560 = 0.3 with PBS solution and reacted with the composition shown in Table 1 below for 30 seconds. 1 ml was transferred to 10 ml of a sterilized PBS aqueous solution containing 0.5% polyoxyethylene sorbitan monooleate and 0.07% lecithin to stop the sterilization reaction. After stirring for 1 minute, it was serially diluted with 9 ml of an aqueous PBS solution containing polyoxyethylene sorbitan monooleate and lecithin. Then, 100 μl of each diluted solution was smeared on an inactivated trypticase soy agar (TSA) medium containing 0.5% polyoxyethylene sorbitan monooleate and 0.07% lecithin, and incubated at 37 ° C. for 48 hours. After culturing, the number of colonies was counted, and the bactericidal effect was evaluated against the following evaluation criteria.
[0024]
Evaluation criteria:
Compared to the negative control (PBS aqueous solution), the number of surviving bacteria is expressed as follows.
~ 1/10 0
1/10 to 1/10 2 +1
1/10 2 to 1/10 3 +2
1/10 3 to 1/10 4 +3
1/10 4 to +4
The larger the evaluation standard value, the higher the bactericidal effect.
The results are shown in Table 1.
[0025]
[Table 1]
[0026]
Table 1 from clear so, all of the embodiments blended vitamin B 5 and B 6 are compared with Comparative Examples 1, 2 and 3 of them were composed of cetylpyridinium chloride (CPC) alone free formulation test solution It is clear that the bactericidal effect is extremely excellent. Moreover, it was confirmed from Comparative Examples 1 and 2 and 3 that the surfactant polyoxyethylene hydrogenated castor oil or polyoxyethylene polyoxypropylene glycol reduces the activity of CPC and reduces the bactericidal effect.
In addition, since vitamins have an effect of promoting cell growth, the addition of them can be expected to improve periodontal disease symptoms such as swelling, redness and bleeding.
[0027]
Example 5 Mouse spray
According to the following formulation, a mouse spray was produced according to a conventional method.
Ingredient name Compounding amount ( % )
Ethanol 10.0
Glycerin 20.0
Polyoxyethylene hydrogenated castor oil (60E. O.) 0. 3
Vitamin B 6 0.01
Perfume 0.1
Sodium saccharin 0.1
Cetylpyridinium chloride 0.05
Sodium citrate 0.08
Tocopherol acetate 0.02
Purified water balance
Total 100.0
About the obtained mouse spray, as a result of evaluating by said sterilization power test, the improvement of the sterilization effect was recognized.
[0028]
【The invention's effect】
According to the present invention, the blended vitamins prevent the incorporation of a cationic bactericidal agent into micelles by a nonionic surfactant, and thus an oral composition that exhibits an excellent bactericidal effect and cell growth promoting action. Provided.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25167599A JP3660169B2 (en) | 1999-09-06 | 1999-09-06 | Oral composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25167599A JP3660169B2 (en) | 1999-09-06 | 1999-09-06 | Oral composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001072561A JP2001072561A (en) | 2001-03-21 |
| JP3660169B2 true JP3660169B2 (en) | 2005-06-15 |
Family
ID=17226354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP25167599A Expired - Lifetime JP3660169B2 (en) | 1999-09-06 | 1999-09-06 | Oral composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3660169B2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6890961B2 (en) * | 2002-02-01 | 2005-05-10 | Micelle Products, Inc. | Clear micellized formulations of β-carotene and method of treating leukoplakia |
| JP5688882B2 (en) * | 2008-06-17 | 2015-03-25 | サンスター株式会社 | Liquid oral composition |
-
1999
- 1999-09-06 JP JP25167599A patent/JP3660169B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001072561A (en) | 2001-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0670711B1 (en) | Antifungal mouthcare compositions | |
| JP2000256155A (en) | Oral composition | |
| JPH08259428A (en) | Oral composition | |
| JP3660169B2 (en) | Oral composition | |
| US7211700B2 (en) | Non-halogenated phenyl substituted phenols, antimicrobial compositions containing the same, and methods of using the same | |
| JP7134770B2 (en) | oral composition | |
| JP2000302673A (en) | Preparation for external use for skin for atopic dermatitis | |
| JPH11322554A (en) | Composition for oral cavity | |
| US20020128323A1 (en) | Non-halogenated phenoxy and/or benzyloxy substituted phenols, antimicrobial compositions containing the same, and methods of using the same | |
| JPH06239723A (en) | Composition for oral cavity | |
| JPH1112144A (en) | Liquid oral composition | |
| US20020119106A1 (en) | Non-halogenated phenyl substituted phenols, antimicrobial compositions containing the same, and methods of using the same | |
| JPH10167939A (en) | Oral composition | |
| JP2000302674A (en) | Selective antibacterial composition | |
| EP2413881A1 (en) | Desensitizing dentifrice exhibiting dental tissue antibacterial agent uptake | |
| JP7774984B2 (en) | Oral composition | |
| JP7725258B2 (en) | Oral composition | |
| JP3821037B2 (en) | Periodontal pathogen adhesion inhibitor and composition for oral cavity having periodontal pathogen adhesion inhibitory action | |
| JPH1059832A (en) | Oral antibacterial agent and oral composition | |
| JP2004026724A (en) | Composition for oral cavity | |
| US20030139478A1 (en) | Non-halogenated hydroxyalkyl-substituted phenol compounds, antimicrobial compositions containing the same, and methods of using the same | |
| JPH09110662A (en) | Halitosis remover and oral composition | |
| JP2000053546A (en) | Mouth rinsing agent | |
| KR100659139B1 (en) | Oral composition with excellent antimicrobial activity | |
| JPH08259427A (en) | Oral composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20040917 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040928 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041125 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050308 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050316 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 3660169 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080325 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090325 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100325 Year of fee payment: 5 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110325 Year of fee payment: 6 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120325 Year of fee payment: 7 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120325 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130325 Year of fee payment: 8 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130325 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140325 Year of fee payment: 9 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |